STUDresearch · Peptide
Liraglutide
Also known as
Victoza · Saxenda · lira
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Peptide
Some talk
Systemic
Subcutaneous
Metabolic / GLP-1 class
Systemic — whole-body GLP-1 effects on appetite, gastric emptying, and glycemic control.
What people say
Liraglutide is a daily injectable GLP-1 medicine discussed for appetite suppression, weight loss and blood-sugar control. It preceded today’s prominent weekly semaglutide and tirzepatide discussion.Victoza and Saxenda have different indications and dose targets.
Doses people talk about
Amounts describe reports and product labels, not an escalation plan. Gray-market formulations are not verified equivalents.
How it may feel
Accounts range from little appetite change to earlier fullness, nausea or fatigue. Some notice a change at 1.2 mg after little at 0.6 mg; others still notice little.
Lower settings in community accounts0.6–1.8 mg SC daily
Nonresponse, appetite change and stronger nausea/fatigue all appear; the same setting does not feel the same to everyone.
Victoza — adult diabetes context1.2 or 1.8 mg SC daily
The 0.6 mg initiation week is for GI tolerance, not adult glycemic maintenance.
Saxenda — adult weight context3 mg SC daily
Lower 0.6/1.2/1.8/2.4 mg settings belong to label escalation; they are not named adult maintenance targets.
Half-life & effect duration
- Half-life in the body
- Under-the-skin injectionAbout 13 hours
- Felt duration people report
- Appetite reportsLess hunger through much of the day, or hunger returning around dinner
- Other experiencesDifferent nausea, tiredness and sleep responses
Cycles people discuss
Clinical use is continuous daily treatment. Community notes also describe pauses, restarts and weeks-on/weeks-off patterns around side effects, cost or travel.
Timing
Morning, midday and evening routines all appear. People choose around appetite, nausea, tiredness, sleep and convenience.
Stacks
Vs newer agents: Often compared or switched toward semaglutide/tirzepatide for weekly convenience.
Watch for
GI class effects: Nausea, vomiting, diarrhea, constipation — classic GLP-1 early-phase burden.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
About 13 hours after a subcutaneous dose of liraglutide.
The blood-level half-life is not a countdown to the end of appetite effects.
Product-specific human pharmacokinetics; not an oral liraglutide estimate or a guaranteed subjective duration.
- Saxenda prescribing information (opens in a new tab)Printed page 5, sections 12.1 and 12.3, EliminationProduct-specific human pharmacokinetics; not an oral liraglutide estimate or a guaranteed subjective duration.
Felt duration people report
Some users describe less hunger through much of the day, while others notice appetite returning around dinner.
Reports also differ on nausea, tiredness and sleep; they do not establish a best injection hour.
The accounts describe appetite patterns rather than measured elimination. Their sleep and stomach responses are not uniform.
- What time do you take your injection, and why? — community accounts (opens in a new tab)Comments by Stay_Curious_1971, Struksy, cupcake927 and jannua82Individual accounts with differing routines, exposure and possible confounders; the thread does not compare timing under controlled conditions.
Other context in this card
- Saxenda: adult amounts and warning context (opens in a new tab)Saxenda current U.S. label §§2, 5, 12.3: daily SC product, adult 3 mg dose versus titration settings, warnings and 13 hour elimination. Independent actual label inspection September 6.U.S. SC product labeling; cannot establish preferred timing or unverified-product safety.
- Victoza: separate adult diabetes amounts (opens in a new tab)Victoza current U.S. label §§2.1–2.2: adult diabetes 0.6 mg tolerability initiation, 1.2/1.8 mg SC daily. Independent actual content inspection September 6.Indication-specific labeled schedule, not a personal plan.
- Liraglutide: mixed lower-setting response (opens in a new tab)Opening 0.6 mg nonresponse and replies describing 1.2 mg response, continued nonresponse and no side effects. Independent actual post/comment inspection September 6.Self-selected different individuals; no controlled dose-response comparison.
- Liraglutide: 1.8 mg symptoms in individual reports (opens in a new tab)Opening 1.8 mg nausea/fatigue and varied resolution in replies. Independent actual post/comment inspection September 6.Different symptom duration and course; cannot establish a personal threshold.
What people say
- Appetite / weight talk: Liraglutide is framed around intake control, GI side effects, and scale speed. forum
- Glycemic control: Landmark T2D programs (e.g. LEAD series) established HbA1c reductions with daily SC liraglutide. trial
- Weight loss: Saxenda-path obesity trials show clinically meaningful weight reduction at higher daily doses than typical T2D starts. trial
- CV outcomes: LEADER CVOT reported CV benefit signals for liraglutide in high-risk T2D — distinct from pure weight-loss marketing. trial
- Community framing: Often called the “daily shot predecessor” to Ozempic-era compounds in forum timelines. forum
Doses people talk about
- Biohacker note: Gray-market multi-dose pens vary in fill accuracy — dose math assumes label truth. forum
- Quality flag: Assume label accuracy only if analytically verified — gray market fill error is common. forum
- Daily titration talk: Community still references step-ups toward multi-mg daily SC (Saxenda-path energy) vs lower T2D-style bands. forum
- T2D-style bands: Medical titration often discussed around 0.6 → 1.2 → 1.8 mg SC daily. trial
- Obesity-style bands: Higher daily maintenance (e.g. up toward 3.0 mg SC daily on Saxenda path) appears in obesity literature and forums. trial
- Framing: Discussed trial/label and community amounts — not a prescription. forum
How it may feel
- Days 1–7: Injection-site reactions and GI/mood changes are discussed during early use; accounts include nausea, fatigue or no obvious change. This card concerns subcutaneous liraglutide, not an oral formulation. forum
- Week 1: GI effects (nausea) often dominate early titration talk more than scale movement. forum
- Weeks 2–8: Appetite quieting and gradual weight change commonly reported as dose escalates. forum
- Months 3–6: Trial weight curves and user logs often show continued slow loss if adherence holds. trial
Around the dose
- Morning vs evening: People describe morning, midday, after-work or bedtime routines around hunger, nausea, fatigue and sleep. Reports conflict rather than establishing a best hour. forum
- Dose-step feel: Reports range from little change at 0.6 mg to appetite change at 1.2 mg or nausea/fatigue at 1.8 mg. These accounts do not measure the 13 hour half-life. forum
- Clock: Once-daily injection; the U.S. labels permit any time of day, independent of meals. trial
Cycles people discuss
- Community off periods: Some pause for GI relief, cost, or travel — not a formal labeled cycle. forum
- Weeks-on / weeks-off discussion: Some self-protocol accounts describe weeks-on/weeks-off instead of indefinite daily use, with cost and caution driving the choice. That remains community talk, not an established common or standardized pattern. forum
- No magic cycle: There is rarely one universal “correct” on/off calendar across forums. forum
- Clinical pattern: Continuous daily use in medical programs, not classic bodybuilding on/off. trial
- Reassess: Stop and reassess if adverse effects appear; this is not medical care. forum
Timing
- Timing: Usually morning or evening consistent daily SC; no universal “best hour” winner. forum
- Timing practicalities: People time doses around side effects, training, and sleep more than perfect PK. forum
- Half-life: ~13 hours supporting once-daily SC dosing in clinical materials. trial
More on what it is
- Where it sits in culture: The daily shot people used before weekly sema/tirz took over fat-loss TikTok/X. forum
- Why people care: Daily GLP-1 option historically used before weekly semaglutide/tirzepatide dominated weight-loss talk. forum
- Research posture: Educational summary of public discussion and literature themes only. forum
- What it is: GLP-1 receptor agonist peptide (Victoza/Saxenda brands in medicine) long discussed in fat-loss and diabetes communities alongside newer dual/triple agonists. trial
- Not the same as: Semaglutide or tirzepatide — different PK, weekly vs daily, and different labeled brands/indications. trial
- Evidence honesty: Strong human RCT base for T2D and weight; gray-market “research liraglutide” is not branded product. trial
Stacks
- Vs newer agents: Often compared or switched toward semaglutide/tirzepatide for weekly convenience. forum
- Less is clearer: Solo runs make personal n=1 easier to interpret than five-compound blasts. forum
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
Watch for
- Muscle loss concern: Rapid weight loss can include lean mass; protein/training talk is common in forums. forum
- Injection site (if injected): Redness, itch, lumps, bruise — technique and product quality matter. forum
- Unknowns: Long-term safety for gray-market preparations is often poorly characterized. forum
- Stack noise: Sides logged on multi-agent stacks cannot be blamed cleanly on one compound. forum
- Seek care red flags: Severe allergic reaction, chest pain, neuro changes, or uncontrolled BP/glucose need real medical care — not forum advice. forum
- GI class effects: Nausea, vomiting, diarrhea, constipation — classic GLP-1 early-phase burden. trial
- Gallbladder / other label risks: Gallbladder disease and acute pancreatitis are explicit warnings. The rodent thyroid C-cell signal underpins MTC/MEN 2 contraindications; human relevance is uncertain. Label cautions also cover increased heart rate, volume-depletion kidney injury, severe GI disease/gastroparesis and aspiration around anesthesia. Saxenda warns of fetal harm in pregnancy. trialanimal
Evidence mix
Mostly community / anecdote tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.